Mobile

A study to evaluate the safety and effectiveness of a quadruple drug regimen (VX-222, telaprevir, peginterferon alfa-2a and ribavirin) in treating chronic hepatitis C virus in subjects with cirrhosis ...

Update Il y a 4 ans
Reference: EUCTR2011-004150-26

A study to evaluate the safety and effectiveness of a quadruple drug regimen (VX-222, telaprevir, peginterferon alfa-2a and ribavirin) in treating chronic hepatitis C virus in subjects with cirrhosis who are treatment naive or nonresponders and relapsers to previous Peg- IFN/Ribavirin therapy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the antiviral efficacy of a quadruple drug regimen (VX-222, telaprevir, Peg-IFN and RBV) in subjects with genotype 1 CHC with compensated cirrhosis, who are treatment naive or were nonresponders (partial or null) or relapsers to previous Peg-IFN/RBV therapy.

Inclusion criteria

  • Chronic Hepatitis C Virus

Links